Psilocybin - Core One Labs
Latest Information Update: 25 Jan 2022
Price :
$50 *
At a glance
- Originator Core One Labs
- Developer Core One Labs; Lobe Sciences; University of Miami
- Class Analgesics; Anti-infectives; Anti-inflammatories; Antidepressants; Antineoplastics; Antipsychotics; Anxiolytics; Behavioural disorder therapies; Dimethylamines; Drug withdrawal therapies; Indoles; Mood stabilisers; Neuropsychotherapeutics; Organophosphorus compounds; Phytotherapies; Small molecules
- Mechanism of Action ATP-binding cassette transporter modulators; Serotonin 5-HT2 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Post-traumatic stress disorders; Traumatic brain injuries
- Research Mental disorders
Most Recent Events
- 21 Jan 2022 Core One Labs files a patent application with the US PTO titled “Production of Psychedelic Compounds” for protection of its novel psilocybin production system
- 28 Sep 2021 Preclinical trials in Post-traumatic stress disorders in USA (unspecified route) as of September 2021
- 28 Sep 2021 Preclinical trials in Traumatic brain injuries in USA (unspecified route) as of September 2021